The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-methyl-6-O-sulfo-.alpha.-D-glucopyranosyl)-(1.fwdarw.4)-O-- (2,3-di-O-methyl-.beta.-D-glucopyranosyl uronic acid)-(1.fwdarw.4)-O-(2,3,6-tri-O-sulfo-.alpha.-D-glucopyranosyl)-(1.fwda- rw.4)-O-(2,3-di-O-methyl-.alpha.-L-idopyranosyl uronic acid)-(1.fwdarw.4)-2,3,6-tri-O-sulfo-.alpha.-D-glucopyranoside or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment of venous thromboembolic events in patients with deep venous thrombosis.